Unknown

Dataset Information

0

Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD.


ABSTRACT:

Background

Batefenterol is a novel bifunctional muscarinic antagonist β2-agonist in development for COPD. The primary objective of this randomized, double-blind, placebo-controlled, active comparator, Phase IIb study was to model the dose-response of batefenterol and select a dose for Phase III development.

Patients and methods

Patients aged ≥40 years with COPD and FEV1 ≥30% and ≤70% predicted normal were randomized equally to batefenterol 37.5, 75, 150, 300, or 600 µg, placebo, or umeclidinium/vilanterol (UMEC/VI) 62.5/25 µg once daily. The primary and secondary endpoints were weighted-mean FEV1 over 0-6 hours post-dose and trough FEV1, analyzed by Bayesian and maximum likelihood estimation Emax of dose-response modeling, respectively, on day 42.

Results

In the intent-to-treat population (N=323), all batefenterol doses demonstrated statistically and clinically significant improvements from baseline vs placebo in the primary and secondary endpoints (191.1-292.8 and 182.2-244.8 mL, respectively), with a relatively flat dose-response. In the subgroup reversible to salbutamol, there were greater differences between batefenterol doses. Lung function improvements with batefenterol ≥150 µg were comparable with those with UMEC/VI. Batefenterol was well tolerated and no new safety signals were observed.

Conclusion

Batefenterol 300 µg may represent the optimal dose for Phase III studies.

SUBMITTER: Crim C 

PROVIDER: S-EPMC6413745 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD.

Crim Courtney C   Watkins Michael L ML   Bateman Eric D ED   Feldman Gregory J GJ   Schenkenberger Isabelle I   Kerwin Edward M EM   Crawford Catriona C   Pudi Krishna K   Ho Shuyen S   Baidoo Charlotte C   Castro-Santamaria Ramiro R  

International journal of chronic obstructive pulmonary disease 20190308


<h4>Background</h4>Batefenterol is a novel bifunctional muscarinic antagonist β<sub>2</sub>-agonist in development for COPD. The primary objective of this randomized, double-blind, placebo-controlled, active comparator, Phase IIb study was to model the dose-response of batefenterol and select a dose for Phase III development.<h4>Patients and methods</h4>Patients aged ≥40 years with COPD and FEV<sub>1</sub> ≥30% and ≤70% predicted normal were randomized equally to batefenterol 37.5, 75, 150, 300,  ...[more]

Similar Datasets

| S-EPMC7814657 | biostudies-literature
| S-EPMC11621982 | biostudies-literature
| S-EPMC9794707 | biostudies-literature
| S-EPMC5973313 | biostudies-literature
| S-EPMC7061154 | biostudies-literature
| S-EPMC3940640 | biostudies-literature
| S-EPMC7947512 | biostudies-literature
| S-EPMC7905605 | biostudies-literature
| S-EPMC4267517 | biostudies-literature
| S-EPMC9227944 | biostudies-literature